Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized Phase II Study of the Reduction in Rectal V100 With the Use of Rectal Spacer Hydrogel in the Management of Intermediate Risk Prostate Cancer Treated With Combined Modality Radiation Therapy

NCT05224869 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT05224869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05224869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized Phase II Study of the Reduction in Rectal V100 With the Use of Rectal Spacer Hydrogel in the Management of Intermediate Risk Prostate Cancer Treated With Combined Modality Radiation Therapy
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Not applicable
Overall status
Terminated
Start date
August 31, 2021
Completion date
January 29, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer